CJC-1295 No DAC Growth Hormone Pulse Guide 2026

Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (Drug Affinity Complex) generates pulsatile growth hormone release patterns nearly identical to endogenous GHRH. With peak amplitudes reaching 300–500% above baseline within 30 minutes of administration. This isn't the sustained elevation you get from the DAC version. The peptide clears rapidly, mimicking the body's natural secretory bursts rather than creating prolonged supraphysiological levels that trigger negative feedback.

Our team has worked with research protocols using both CJC-1295 variants across hundreds of applications. The difference between them isn't subtle. It's mechanistic. One amplifies your body's existing pulses. The other replaces them.

What is CJC-1295 without DAC and how does it differ from the DAC version?

CJC-1295 without DAC is a synthetic analogue of growth hormone releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotrophs, triggering episodic growth hormone secretion with a half-life of approximately 30 minutes. Unlike CJC-1295 with DAC. Which extends half-life to 6–8 days through albumin binding. The no-DAC version clears quickly, producing short-duration GH pulses that preserve the body's natural secretory rhythm and avoid sustained receptor desensitisation.

Here's what most overviews miss: CJC-1295 no DAC growth hormone pulse protocols aren't designed to flood receptors continuously. They work by amplifying the amplitude of naturally occurring secretory episodes. The 8–12 pulses your pituitary already generates daily. Without disrupting the ultradian rhythm that protects receptor sensitivity. The DAC modification creates sustained elevation that physiologically resembles exogenous growth hormone administration more than it resembles natural GHRH activity. This article covers the exact mechanisms that differentiate pulsatile from sustained agonism, accurate reconstitution and dosing protocols for research applications, and what preparation mistakes invalidate results entirely.

CJC-1295 No DAC Mechanism: GHRH Receptor Activation Without Albumin Binding

CJC-1295 without DAC functions as a direct GHRH receptor agonist at the anterior pituitary. When administered subcutaneously, the peptide enters systemic circulation and crosses into the hypothalamic-pituitary portal system, where it binds to GHRH receptors (GHRHR) on somatotroph cells. The specialised anterior pituitary cells responsible for growth hormone synthesis and secretion. Receptor activation triggers adenylyl cyclase, elevating intracellular cAMP and mobilising calcium stores, which initiates vesicular exocytosis of pre-synthesised GH granules into circulation.

The critical structural difference: CJC-1295 no DAC lacks the lysine-maleimide modification that allows the DAC version to form covalent bonds with serum albumin. Without albumin binding, plasma half-life remains under 30 minutes. Consistent with endogenous GHRH. Peak GH response occurs 20–40 minutes post-injection, returns to baseline within 90–120 minutes, and generates no detectable peptide presence beyond three hours. This pharmacokinetic profile preserves pulsatility: each dose creates one discrete secretory episode rather than prolonged receptor occupancy.

Research applications using CJC-1295 no DAC typically administer doses of 100–200 mcg per injection, timed to coincide with natural GH pulse windows. Most commonly pre-sleep (aligning with the nocturnal secretory surge) or post-training (exploiting the exercise-induced GH pulse). Multiple daily dosing isn't standard because the peptide doesn't accumulate; each administration is an independent event.

Reconstitution and Storage: Preserving Peptide Integrity

CJC-1295 without DAC is supplied as lyophilised powder requiring reconstitution with bacteriostatic water before use. The lyophilised form must be stored at −20°C before mixing. Once reconstituted, the solution is stable at 2–8°C for up to 28 days. Temperature excursions above 8°C cause irreversible aggregation of the peptide backbone, rendering it biologically inactive without visible degradation.

Reconstitution protocol: Use 2 mL bacteriostatic water per 2 mg vial for a final concentration of 1 mg/mL (1000 mcg/mL). Inject the water slowly down the side of the vial. Never directly onto the lyophilised cake, which can denature surface peptides through mechanical shear. Swirl gently to dissolve; do not shake. The solution should be clear and colourless. Any cloudiness, particulate matter, or discolouration indicates peptide degradation. Discard immediately.

Dosing accuracy depends on syringe precision. A standard 100 mcg dose equals 0.1 mL from a 1 mg/mL solution. Use insulin syringes (U-100, 0.5 mL or 1 mL capacity) with 0.01 mL gradations for accurate measurement. Dosing errors are the most common protocol failure we've seen. Researchers frequently underestimate the importance of syringe resolution when working at microgram scale.

CJC-1295 No DAC vs DAC vs Modified GRF (1-29): Research Application Comparison

Key Takeaways

• CJC-1295 without DAC produces growth hormone pulses lasting 90–120 minutes with peak response at 20–40 minutes post-injection, mimicking natural GHRH episodic activity.
• The peptide has a plasma half-life under 30 minutes because it lacks the albumin-binding DAC modification, requiring daily or multiple-daily dosing for sustained protocols.
• Standard research doses range from 100–200 mcg per injection, reconstituted to 1 mg/mL concentration using bacteriostatic water and stored refrigerated at 2–8°C for up to 28 days.
• Temperature excursions above 8°C cause irreversible peptide aggregation. Lyophilised powder must be frozen at −20°C before reconstitution, and reconstituted solution must remain refrigerated.
• CJC-1295 no DAC preserves pulsatile GH secretion patterns, avoiding the sustained receptor occupancy and negative feedback associated with DAC-modified or exogenous growth hormone protocols.

What If: CJC-1295 No DAC Scenarios

What If the Reconstituted Solution Develops Cloudiness After One Week?

Discard it immediately. Cloudiness indicates peptide aggregation or bacterial contamination, both of which render the solution ineffective and potentially unsafe. Aggregated peptides lose biological activity and cannot be recovered by filtration or re-mixing. Bacterial contamination in bacteriostatic water is rare but catastrophic; even if the solution appears clear after cloudiness resolves, structural integrity is already compromised. Reconstitute a fresh vial and verify refrigeration temperature hasn't fluctuated above 8°C.

What If You Miss the Intended Dosing Window During a Pulsatile Protocol?

Administer the dose as soon as you remember if fewer than four hours have passed since the planned injection time, then continue the regular schedule. If more than four hours have elapsed, skip that dose entirely and resume at the next scheduled time. Do not double-dose to compensate. CJC-1295 no DAC works through discrete episodic pulses; the goal is consistent amplification of natural rhythm, not cumulative exposure. Missing one pulse doesn't invalidate the protocol, but disrupting the rhythm with irregular timing reduces the physiological alignment that makes pulsatile administration valuable.

What If You're Combining CJC-1295 No DAC with a GHRP Like Ipamorelin?

Dose them simultaneously or within 15 minutes of each other to exploit synergistic GH release through dual-pathway activation. GHRH receptor agonism (CJC-1295) and ghrelin receptor agonism (ipamorelin) produce additive, not competitive, effects. Typical research combinations use 100–200 mcg CJC-1295 no DAC with 200–300 mcg ipamorelin per pulse. The additive effect can increase peak GH amplitude by 50–100% compared to either peptide alone, based on pharmacological studies in endocrine research models. Keep total pulse frequency to 1–3× daily to avoid receptor desensitisation from chronic stimulation.

The Unvarnished Truth About CJC-1295 No DAC vs DAC Protocols

Here's the honest answer: the 'convenience' of weekly DAC dosing comes with a tradeoff most suppliers don't mention. CJC-1295 with DAC creates sustained receptor occupancy that physiologically resembles exogenous growth hormone administration more than it resembles natural GHRH activity. Your body's pituitary doesn't secrete GH continuously. It pulses 8–12 times per day in response to ultradian rhythm, sleep cycles, and metabolic signals. Those intervals between pulses aren't wasted time; they're when receptors reset sensitivity.

The DAC modification bypasses that rhythm entirely. You get prolonged elevation, but at the cost of blunted peak amplitude over time and increased negative feedback signalling that can suppress endogenous secretion. CJC-1295 no DAC requires more frequent administration, but it works with your physiology instead of overriding it. The pulsatile approach preserves receptor sensitivity, maintains natural feedback loops, and avoids the metabolic adaptation that chronic elevation triggers. If your research goal is amplifying natural GH dynamics rather than replacing them, the no-DAC version is the mechanistically appropriate choice. Even if it's less convenient.

Dosing Precision and Common Protocol Errors

The most frequent mistake researchers make with CJC-1295 no DAC isn't reconstitution technique. It's syringe resolution. A 100 mcg dose from a 1 mg/mL solution requires drawing exactly 0.1 mL. Standard 1 mL insulin syringes have gradations every 0.01 mL (10 units on a U-100 syringe), which allows adequate precision. Using a 3 mL syringe with 0.1 mL gradations. Common in general lab supply kits. Introduces ±50 mcg dosing error, which is unacceptable at this scale.

Another error: injecting air into the vial while drawing solution. The resulting positive pressure pushes liquid back through the needle on subsequent draws, pulling contaminants into the vial and reducing dose accuracy. Correct technique: insert needle with no plunger pressure, invert vial, draw slowly without introducing air. If you need to equalise vial pressure after multiple draws, inject air before inserting the needle fully through the stopper. Not after.

Timing matters as much as dose. CJC-1295 no DAC peaks at 20–40 minutes and clears within two hours. Administering it four hours before a planned activity expecting peak GH response means you've missed the window entirely. Pre-sleep dosing works because the peptide's peak aligns with the body's largest natural nocturnal pulse. Post-training dosing works because exercise creates a brief GH pulse window that the peptide amplifies. Random midday dosing outside these windows produces a measurable pulse but lacks the synergistic amplification that makes pulsatile protocols effective.

Real Peptides produces CJC-1295 no DAC and related research peptides through small-batch synthesis with full amino acid sequencing verification. Every batch includes third-party purity testing via HPLC. Because at microgram dosing scales, even 5% impurity compounds significantly. Our CJC1295 Ipamorelin blend combines both peptides in verified ratios for dual-pathway research applications, and our commitment to batch-level traceability extends across our full catalogue. Including compounds like MK 677 for ghrelin pathway research and Hexarelin for comparative GHRP studies.

The difference between research-grade and commercial-grade peptides shows up in reconstitution clarity, dosing consistency across vials, and stability under refrigeration. If your peptide degrades in ten days instead of twenty-eight, the issue isn't storage. It's synthesis purity. Impurities accelerate aggregation, reduce bioactivity, and introduce variables that invalidate controlled research. There's no recovery protocol for compromised peptides; starting with verified product integrity is the only option.

CJC-1295 no DAC isn't a convenience peptide. It's a precision tool for amplifying physiological GH dynamics without overriding them. And that precision starts before the first injection, at the synthesis and verification stage most researchers never see.